Wasn't what I was expecting to come out of the trading halt but interesting all the same
● Emyria has signed a letter of intent (LOI) with Cydelic - a private company based in Seattle developing tools and technologies that help track the wellbeing of patients before, during and after psychedelic-assisted therapy ● Emyria plans to work with Cydelic across all of its psychedelic-assisted therapy programs to capture unique biometric data that can assist with real-time patient safety and dose response analysis and registration of psychedelic-assisted therapy ● Emyria’s phase 2b MDMA-assisted therapy trial for severe Post Traumatic Stress Disorder (PTSD), EMDMA-001, developed with registered charity Mind Medicine Australia (MMA), [See ASX announcement 05 May 2021] will be the first program to incorporate Cydelic technology and is expected to be one of the first programs in the world to incorporate remote patient monitoring within MDMA-assisted therapy ● EMDMA-001’s leading psychotherapist is MMA’s clinical lead Nigel Denning who has completed therapist training with the Multidisciplinary Association for Psychedelic Studies (MAPS) this week and is a co-lead of MMA’s Certificate of Psychedelic Assisted Therapy (CPAT) ● The recent TGA decision not to reschedule MDMA from Schedule 9 to 8 at this time places greater importance on clinical trials and Real-World Data to develop evidence-based practices for these treatments to improve patient access ● Emyria is committed to advancing its proprietary MDMA-analogue program to deliver new registered treatments for a range of psychiatric and neurological indications
EMD Price at posting:
37.0¢ Sentiment: Buy Disclosure: Held
